Skip to main navigation
logo

Investor Relations

  • Archived Advaxis News Releases
  • Archived Advaxis Events & Presentations
  • Archived Advaxis Quarterly Results

News Release Details

OS Therapies Announces Dosing of First Patient in a Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma

Go Back
October 22, 2021
OS Therapies Announces Dosing of First Patient in a Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma.pdf 40.4 KB

© 2023 Advaxis, Inc..     All rights reserved.

  • Facebook
  • Twitter
  • LinkedIn
  • Google+